Business Wire

Members of Project Management Institute Community Take the TED Mainstage to Share Big, Bold, Creative Ideas at New Virtual Event

Share

Project Management Institute (PMI), the world's leading association for the project management profession, is shining a light on the talents and ideas of the project community during TED@PMI: Action + Impact, a virtual event on 25-26 September 2020. Open to the public, this free event will celebrate a community of doers and the vision, inspiration and mesmerizing awe of turning big ideas into action.

The TED@PMI Talks were sourced directly from the PMI community. More than 600,000 members and 500 employees, as well as more than 330,000 certification holders in China had the chance to submit their ideas. Through a multi-round process, a team of TED coaches, including TED@PMI Curator Sally Kohn, vetted the entries to find the most compelling stories. From the applicant pool, 12 individuals were selected to go through the TED Talk speaker process, where coaches provide one-on-one storytelling guidance, talk development and public speaking training to sharpen and hone ideas and talks.

During the event, the speakers will take the TED@PMI mainstage across two days, but the event is not just about the Talks. Pre-, during and post-event activities make it possible to build community through experience. Start the event with a total body workout or guided meditation with fellow attendees. Before the TED@PMI mainstage session, learn how to brew the perfect cappuccino and craft the best cocktail to enjoy during the event. Unwind after the mainstage session during the virtual DJ dance parties or by diving deeper into the speakers’ stories during speaker panel discussions. Stay connected with other attendees by creating and exchanging virtual business cards.

“These individuals are not just dedicated to telling their story, they’re dedicated to taking action and making an impact,” said Sunil Prashara, President and CEO of PMI. “It’s people like this - those not afraid to turn an idea into reality - who solve our world’s biggest problems.”

The 12 TED@PMI speakers hail from around the world, representing PMI’s global footprint. From trauma and healing, to communication and community, to project management and social change, these speakers tell their boldest and most inspiring stories.

  • Chiwuike Amaechi (Lagos, Nigeria): Storytelling as tradition and transformation that connects us all
  • Khulan Batkhuyag (Ulaanbaatar, Mongolia): Permanent life-lessons from the nomadic life of Mongolians
  • Wale Elegbede (Rochester, N.Y., U.S.): Stop seeing discrimination as “their” problem and see it as “our problem” — all of us
  • Kristin Jones (Springfield, Pa., U.S.): How to talk with your kids about sexual assault, without spreading shame
  • Betsy Kauffman (Charlotte, N.C., U.S.): My son with autism is really blunt — and we should all be more like him
  • Dinae Knox (Chicago, Ill., U.S.): How to turn life’s depleted soil into rich compost
  • YeYoon Kim (Singapore): What kindergarteners taught me about the gift of asking for help
  • Kathy Mendias (Bonita, Calif., U.S.): The case for crying — a lot
  • Billy SamuelMwape (Lusaka, Zambia): What if we saw kids with special needs not as problems, but projects
  • Danielle Torley (Destin, Fla., U.S.): One woman’s journey from losing a family member in a fire to… becoming a fire dancer?!?
  • Mounina Tounkara (Nice, France): The immigrant experience of racism and confronting outsider/insider bias
  • Jess Woods (Tucson, Ariz., U.S.): Avoiding the prickly cactuses of life — literally and figuratively

The TED@PMI partnership is all about identifying thought-leaders and unearthing the best ideas from the project management community. Every year, the TED Institute works with a group of carefully selected organizations like PMI to identify their best inventors, connectors, and creators.

To register for free today or to learn more about the speakers, visit: TED.PMI.org.

About Project Management Institute (PMI)
Project Management Institute (PMI) is the world's leading association for those who consider project, program or portfolio management their profession. Through global advocacy, collaboration, education and research, we work to prepare more than three million professionals around the world for The Project Economy: the coming economy in which work, and individuals, are organized around projects, products, programs and value streams Now 50 years in the making, we work in nearly every country around the world to advance careers, improve organizational success and further mature the project management profession through globally-recognized standards, certifications, communities, resources, tools, academic research, publications, professional development courses and networking opportunities. As part of the PMI family, ProjectManagement.com creates online global communities that deliver more resources, better tools, larger networks and broader perspectives. Visit us at www.PMI.org, www.projectmanagement.com, www.facebook.com/PMInstitute and on Twitter @PMInstitute.

About TED
TED is a nonprofit organization devoted to Ideas Worth Spreading, often in the form of short talks delivered by leading thinkers and doers. Many of these talks are given at TED conferences, intimate TED Salons, and thousands of independently organized TEDx events around the world. Videos of these talks are made available, free, on TED.com and other platforms. Audio versions of TED Talks are published to TED Talks Daily, available on all podcast platforms.

TED's open and free initiatives for spreading ideas include TED.com, where new TED Talk videos are posted daily; TEDx, which licenses thousands of individuals and groups to host local, self-organized TED-style events around the world; the TED Fellows program, which selects innovators from around the globe to amplify the impact of their remarkable projects and activities; The Audacious Project, which surfaces and funds critical ideas that have the potential to impact millions of lives; TED Translate, which crowdsources the subtitling of TED Talks so that big ideas can spread across languages and borders; and the educational initiative TED-Ed. TED also has a growing library of original podcasts, including The TED Interview with Chris Anderson, WorkLife with Adam Grant, Pindrop and TEDxSHORTS.

Follow TED on Twitter, Facebook, Instagram and LinkedIn.

Contact information

Media:
Rachael Ballard, Project Management Institute
Rachael.Ballard@pmi.org
443-618-7014

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ESMO 2020: Cabometyx ® (cabozantinib) in Combination With Opdivo ® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 18:30:00 CESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 12:55:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 12:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 09:30:00 CESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 08:00:00 CESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline ® Autogel ® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 07:00:00 CESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel®(lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatmen

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom